Monte Rosa Therapeutics, Inc. Basic Shares Outstanding (Weighted Average)
Monte Rosa Therapeutics, Inc. (GLUE) reported Basic Shares Outstanding (Weighted Average) of 101.48 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-06
- Monte Rosa Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 101.48M shares, a 23.47% increase year-over-year.
- Monte Rosa Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 99.88M shares, a 21.59% increase year-over-year.
- Monte Rosa Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 85.55M shares, a 4.18% increase year-over-year.
- Monte Rosa Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 82.40M shares, a 0.47% increase year-over-year.
- Monte Rosa Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 83.07M shares, a 12.40% increase from fiscal 2024.
- Monte Rosa Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 73.91M shares, a 43.80% increase from fiscal 2023.
- Monte Rosa Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 51.40M shares, a 8.83% increase from fiscal 2022.
- Monte Rosa Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 47.23M shares, a 88.91% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 101.48M shares 10-Q · filed 2026-08-06 | 100.69M shares 10-Q · filed 2026-08-06 | 95.64M shares derived: average of 3 quarters · filed 2026-08-06 | 92.33M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 99.88M shares 10-Q · filed 2026-05-07 | 92.72M shares derived: average of 2 quarters · filed 2026-05-07 | 89.28M shares derived: average of 3 quarters · filed 2026-05-07 | 87.50M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 85.55M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 83.97M shares derived: average of 2 quarters · filed 2026-03-17 | 83.38M shares derived: average of 3 quarters · filed 2026-08-06 | 83.07M shares 10-K · filed 2026-03-17 |
| 2025-09-30 | 82.40M shares 10-Q · filed 2025-11-06 | 82.29M shares derived: average of 2 quarters · filed 2026-08-06 | 82.25M shares 10-Q · filed 2025-11-06 | 82.21M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 82.19M shares 10-Q · filed 2026-08-06 | 82.17M shares 10-Q · filed 2026-08-06 | 82.15M shares derived: average of 3 quarters · filed 2026-08-06 | 82.12M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 82.15M shares 10-Q · filed 2026-05-07 | 82.13M shares derived: average of 2 quarters · filed 2026-05-07 | 82.09M shares derived: average of 3 quarters · filed 2026-05-07 | 79.38M shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 82.12M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 82.07M shares derived: average of 2 quarters · filed 2026-03-17 | 78.45M shares derived: average of 3 quarters · filed 2026-03-17 | 73.91M shares 10-K · filed 2026-03-17 |
| 2024-09-30 | 82.01M shares 10-Q · filed 2025-11-06 | 76.62M shares derived: average of 2 quarters · filed 2025-11-06 | 71.17M shares 10-Q · filed 2025-11-06 | 67.60M shares derived: average of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | 71.23M shares 10-Q · filed 2025-08-07 | 65.70M shares 10-Q · filed 2025-08-07 | 62.79M shares derived: average of 3 quarters · filed 2025-08-07 | 59.55M shares derived: average of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | 60.16M shares 10-Q · filed 2025-05-08 | 58.57M shares derived: average of 2 quarters · filed 2025-05-08 | 55.65M shares derived: average of 3 quarters · filed 2025-05-08 | 54.10M shares derived: average of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | 56.99M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 53.40M shares derived: average of 2 quarters · filed 2025-03-20 | 52.08M shares derived: average of 3 quarters · filed 2025-03-20 | 51.40M shares 10-K · filed 2025-03-20 |
| 2023-09-30 | 49.81M shares 10-Q · filed 2024-11-07 | 49.62M shares derived: average of 2 quarters · filed 2024-11-07 | 49.53M shares 10-Q · filed 2024-11-07 | 49.38M shares derived: average of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | 49.43M shares 10-Q · filed 2024-08-08 | 49.39M shares 10-Q · filed 2024-08-08 | 49.23M shares derived: average of 3 quarters · filed 2024-08-08 | 48.61M shares derived: average of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | 49.35M shares 10-Q · filed 2024-05-09 | 49.13M shares derived: average of 2 quarters · filed 2024-05-09 | 48.33M shares derived: average of 3 quarters · filed 2024-05-09 | 47.91M shares derived: average of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | 48.91M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | 47.82M shares derived: average of 2 quarters · filed 2024-03-14 | 47.44M shares derived: average of 3 quarters · filed 2024-03-14 | 47.23M shares 10-K · filed 2024-03-14 |
| 2022-09-30 | 46.73M shares 10-Q · filed 2023-11-09 | 46.70M shares derived: average of 2 quarters · filed 2023-11-09 | 46.67M shares 10-Q · filed 2023-11-09 | 46.69M shares derived: average of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | 46.67M shares 10-Q · filed 2023-08-10 | 46.63M shares 10-Q · filed 2023-08-10 | 46.67M shares derived: average of 3 quarters · filed 2023-08-10 | 46.50M shares derived: average of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | 46.60M shares 10-Q · filed 2023-05-11 | 46.67M shares derived: average of 2 quarters · filed 2023-05-11 | 46.44M shares derived: average of 3 quarters · filed 2023-05-11 | 36.10M shares derived: average of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | 46.75M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 46.37M shares derived: average of 2 quarters · filed 2023-03-16 | 32.60M shares derived: average of 3 quarters · filed 2023-03-16 | 25.00M shares 10-K · filed 2023-03-16 |
| 2021-09-30 | 45.99M shares 10-Q · filed 2022-11-10 | 25.53M shares derived: average of 2 quarters · filed 2022-11-10 | 17.75M shares 10-Q · filed 2022-11-10 | |
| 2021-06-30 | 5.07M shares 10-Q · filed 2022-08-11 | 3.40M shares 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |